Primary trastuzumab resistance: New tricks for an old drug

Annals of the New York Academy of Sciences

Volumn 1210, Issue 1, 2010, Pages 53-65

  Wilken, Jason A ^a   Maihle, Nita J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; EGFR ErbB HER; Primary resistance; Targeted therapeutics; Trastuzumab herceptin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BORTEZOMIB; CETUXIMAB; DOCETAXEL; GEFITINIB; METFORMIN; NAVELBINE; PERTUZUMAB; RETINOIC ACID; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLONY FORMATION; DISTANT METASTASIS; DRUG BINDING; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; LUNG CANCER; OVARY CANCER; PHENOTYPIC VARIATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; BREAST TUMOR; CANCER STAGING; CELL DIVISION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; EXTRACELLULAR MATRIX; FEMALE; PATHOLOGY; PHOSPHORYLATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; FEMALE; HUMANS; NEOPLASM STAGING; PHOSPHORYLATION; RECEPTOR CROSS-TALK; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 78349264613     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05782.x     Document Type: Article

References (91)

1. Allison, M. 2010. The HER2 testing conundrum. Nat. Biotechnol. 28: 117-119.
2. Nahta, R., M.C. Hung & F.J. Esteva 2004. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64: 2343-2346.
3. Arnould, L. et al 2006. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94: 259-267.
4. Pegram, M. et al 1999. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251.
5. Slamon, D.J. et al 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792.
6. Pupa, S.M. et al 1993. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923.
7. Zabrecky, J.R. et al 1991. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem. 266: 1716-1720.
8. Codony-Servat, J. et al 1999. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59: 1196-1201.
9. Lafky, J.M. et al 2008. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta 1785: 232-265.
10. Molina, M.A. et al 2001. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61: 4744-4749.
11. Christianson, T.A. et al 1998. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 58: 5123-5129.
12. Anido, J. et al 2006. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25: 3234-3244.
13. Drebin, J.A. et al 1985. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 697-706.
14. Hurwitz, E. et al 1995. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA 92: 3353-3357.
15. Klapper, L.N. et al 2000. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60: 3384-3388.
16. Baselga, J. & S.M. Swain 2009. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9: 463-475.
17. Spector, N.L. & K.L. Blackwell 2009. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27: 5838-5847.
18. Pohlmann, P.R., I.A. Mayer & R. Mernaugh 2009. Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15: 7479-7491.
19. Harris, L.N. et al 2007. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13: 1198-1207.
20. Wolff, A.C. et al 2007. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25: 118-145.
21. Romond, E.H. et al 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353: 1673-1684.
22. Doherty, J.K. et al 1999. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc. Natl. Acad. Sci. USA 96: 10869-10874.
23. Scott, G.K. et al 1993. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol. Cell Biol. 13: 2247-2257.
24. Pedersen, K. et al 2009. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell Biol. 29: 3319-3331.
25. Scaltriti, M. et al 2007. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 99: 628-638.
26. Molina, M.A. et al 2002. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 8: 347-353.
27. Saez, R. et al 2006. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin. Cancer Res. 12: 424-431.
28. Sperinde, J. et al 2010. Quantitation of p95HER2 in paraffin sections using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin. Cancer Res. 16: 4226-4235.
29. Brodowicz, T. et al 1997. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int. J. Cancer 73: 875-879.
30. Ghedini, G.C. et al 2010. Shed HER2 extracellular domain in HER2-mediated tumor growth and in Trastuzumab susceptibility. J. Cell Physiol.
31. Ali, S.M. et al 2008. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 113: 1294-1301.
32. Lennon, S. et al 2009. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J. Clin. Oncol. 27: 1685-1693.
33. Witzel, I. et al 2010. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res. Treat. 123: 437-445.
34. Arnould, L. et al 2007. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin. Cancer Res. 13: 6404-6409.
35. Ginestier, C. et al 2007. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26: 7163-7169.
36. Weinstein, I.B. 2002. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
37. Narayan, M. et al 2009. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res. In Press.
38. Dua, R. et al 2010. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res. Treat. 122: 685-697.
39. Yotsumoto, F. et al 2010. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. Int. J. Cancer. In Press.
40. Yonemori, K. et al 2010. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. J. Surg. Oncol. 101: 222-227.
41. Jerome, L. et al 2006. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 66: 7245-7252.
42. Lu, Y. et al 2001. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 93: 1852-1857.
43. Vegran, F. et al 2009. Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. Br. J. Cancer 101: 1357-1364.
44. Zhuang, G. et al 2010. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70: 299-308.
45. Martin, K.J. et al 2008. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 3: e2994.
46. Fournier, M.V. et al 2006. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res. 66: 7095-7102.
47. Cavalloni, G. et al 2008. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab. Anti-cancer Drugs 19: 689-696.
48. Mocanu, M.M. et al 2005. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett. 227: 201-212.
49. Palyi-Krekk, Z. et al 2007. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur. J. Cancer 43: 2423-2433.
50. Price-Schiavi, S.A. et al 2002. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 99: 783-791.
51. Nagy, P. et al 2005. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 65: 473-482.
52. Fessler, S.P. et al 2009. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res. Treat. 118: 113-124.
53. Hikita, S.T. et al 2008. MUC1* mediates the growth of human pluripotent stem cells. PLoS ONE 3: e3312.
54. Mahanta, S. et al 2008. A minimal fragment of MUC1 mediates growth of cancer cells. PLoS ONE 3: e2054.
55. Kulkarni, S. et al 2009. Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene 29: 1339-1350.
56. Carragher, N.O. & M.C. Frame 2002. Calpain: a role in cell transformation and migration. Int. J. Biochem. Cell Biol. 34: 1539-1543.
57. Citri, A., B.S. Kochupurakkal & Y. Yarden 2004. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3: 51-60.
58. Chandarlapaty, S. et al 2010. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29: 325-334.
59. Leow, C.C. et al 2009. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther. 8: 2131-2141.
60. Hamel, S. et al 2010. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Res. Treat. 120: 47-57.
61. Belkhiri, A. et al 2008. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin. Cancer Res. 14: 4564-4571.
62. Yonemori, K. et al 2009. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med. Oncol. 26: 344-349.
63. Nagata, Y. et al 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
64. Migliaccio, I. et al 2008. PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). In Proceedings of the San Antonio Breast Cancer Symposium: Abstract 34. San Antonio, TX .
65. Gori, S. et al 2009. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann. Oncol. 20: 648-654.
66. O'Brien, N.A. et al 2010. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol. Cancer Ther. 9: 1489-1502.
67. Kataoka, Y. et al 2010. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann. Oncol. 21: 255-262.
68. Koninki, K. et al 2010. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett. 294: 211-219.
69. Gu, L. et al 2009. Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. Clin. Cancer Res. 15: 7196-7206.
70. Cheng, Y. et al 2010. Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS ONE 5: e9715.
71. Weigelt, B. et al 2009. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat. 122: 35-43.
72. Lesniak, D. et al 2009. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 69: 8620-8628.
73. Delord, J.P. et al 2010. Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. Br. J. Cancer 103: 61-72.
74. Jain, A. et al 2010. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 70: 1989-1999.
75. Wilken, J.A., K.T. Webster & N.J. Maihle 2010. Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics. J. Ovarian Res. 3: 7.
76. Tari, A.M. et al 2002. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 21: 5224-5232.
77. Cardoso, F. et al 2006. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol. Cancer Ther. 5: 3042-3051.
78. Damiano, V. et al 2009. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin. Cancer Res. 15: 6921-6930.
79. Vazquez-Martin, A. et al 2010. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res. Treat. In Press.
80. Papanas, N., E. Maltezos & D.P. Mikhailidis 2010. Metformin and cancer: licence to heal? Expert Opin. Investig. Drugs 19: 913-917.
81. Martin-Castillo, B. et al 2010. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann. Oncol. 21: 187-189.
82. Liang, K. et al 2003. Sensitization of breast cancer cells to radiation by trastuzumab. Mol. Cancer Ther. 2: 1113-1120.
83. Barok, M. et al 2007. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 6: 2065-2072.
84. Barok, M. et al 2008. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett. 260: 198-208.
85. Junttila, T.T. et al 2010. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 70: 4481-4489.
86. Wu, K. et al 2002. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol. Cancer Ther. 1: 695-706.
87. Boerner, J.L., A. Danielsen & N.J. Maihle 2003. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp. Cell Res. 284: 111-121.
88. Lin, J.H. et al 2007. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells. J. Virol. 81: 5705-5713.
89. Chang, C.J. et al 2006. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur. J. Clin. Invest. 36: 588-596.
90. Kauraniemi, P. et al 2004. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 23: 1010-1013.
91. Tanner, M. et al 2004. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol. Cancer Ther. 3: 1585-1592.